Tobin Juvenal Sells 20,863 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 20,863 shares of Castle Biosciences stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $25.24, for a total transaction of $526,582.12. Following the completion of the sale, the insider directly owned 86,825 shares in the company, valued at approximately $2,191,463. The trade was a 19.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Trading Up 0.3%

NASDAQ CSTL opened at $25.90 on Wednesday. The company has a quick ratio of 5.11, a current ratio of 5.26 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $770.03 million, a P/E ratio of -30.47 and a beta of 1.09. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28. The firm has a 50-day moving average price of $34.09 and a 200 day moving average price of $31.78.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The company had revenue of $81.88 million for the quarter, compared to analyst estimates of $81.19 million. Equities research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CSTL shares. Lake Street Capital upped their price objective on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Robert W. Baird raised their target price on Castle Biosciences from $41.00 to $44.00 and gave the company an “outperform” rating in a report on Friday, February 27th. BTIG Research boosted their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Guggenheim upped their price target on shares of Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, March 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.57.

Institutional Trading of Castle Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CSTL. Federated Hermes Inc. bought a new stake in Castle Biosciences in the fourth quarter worth approximately $26,000. Farther Finance Advisors LLC raised its holdings in Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue bought a new position in Castle Biosciences during the third quarter valued at about $35,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter worth about $35,000. Finally, CWM LLC boosted its stake in shares of Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after acquiring an additional 853 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.